SCHEDULE: Alpha Capital Anstalt Discloses 0.51% Stake in ALXCRYPTO
Beneficial Ownership Report
Alpha Capital Anstalt has filed an Amendment No. 4 to Schedule 13G, reporting beneficial ownership of 0.51% of ALXCRYPTO HOLDINGS, INC. common stock.
Summary
- Alpha Capital Anstalt reported beneficial ownership of 36,003 shares of ALXCRYPTO HOLDINGS, INC. common stock.
- This represents 0.51% of the issuer's outstanding common stock.
- The percentage is based on 7,049,999 shares outstanding as of November 20, 2025, as reported in a DEF-14A filing on December 15, 2025.
- Alpha Capital Anstalt, a Liechtenstein entity, holds sole voting and dispositive power over all 36,003 shares.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral disclosure, providing transparency on a passive ownership stake without indicating any significant positive or negative operational or financial developments for the issuer.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures of passive beneficial ownership, providing transparency on significant institutional holdings but not typically offering insights into broader industry trends or competitive positioning.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant, albeit passive, institutional investor's stake in the company.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2025-11-20 | Date shares outstanding were reported (7,049,999 shares) in a DEF-14A filing. |
| 2025-12-15 | Date DEF-14A was filed, reporting shares outstanding. |
| 2026-01-28 | Date of event requiring the filing of this statement. |
| 2026-01-29 | Date the Schedule 13G Amendment No. 4 was signed. |
Keywords
ALXCRYPTO HOLDINGS, QUALIGEN THERAPEUTICS, Alpha Capital Anstalt, Schedule 13G, beneficial ownership, common stock, equity stake, institutional ownership, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.